Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports the development of the first rodent model for androgenetic alopecia, demonstrating that overexpression of androgen receptors in mice delays hair regeneration and can be used to test new treatments.

This review discusses the role of the androgen receptor in breast cancer diagnosis and treatment, and notes a lack of new research results on its therapeutic potential.

This article reviews the molecular mechanisms involved in androgenetic alopecia and the androgen's paradoxical role in hair growth, but reports no new experimental findings.

This review explores various substances with potential antiandrogenic effects for treating acne, highlighting evidence for isotretinoin, and discusses the future consideration of 5 alpha-reductase inhibitors as antiandrogens.

In this study, researchers developed a sensitive assay to measure the inhibition of steroid 5-α reductase (5AR) by chemicals like finasteride and dutasteride, revealing species-specific differences in inhibitor efficacy between human and fish cell lines.

This article addresses the mechanisms of androgenic alopecia and seeks to clarify misconceptions, but it reports no new empirical findings and calls for further controlled studies.

In this study, ELE was found to protect against oxidative stress-induced testosterone reduction in TM3 Leydig cells by increasing testosterone synthesis and decreasing its conversion.

This research reported that AKR1C enzyme expression, particularly AKR1C4, in scalp sebaceous glands decreases with age, suggesting potential age-related changes in androgen metabolism affecting hair follicle health. Additionally, sulforaphane treatment increased AKR1C expression in related cell types.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

This study found that the total testosterone/dihydrotestosterone ratio is significantly higher in women with polycystic ovary syndrome and is associated with a worse metabolic profile in both PCOS and healthy women.

This animal study found that finasteride, a 5-alpha reductase type 2 inhibitor, decreased dihydrotestosterone levels and c-Fos protein activation in the rat brain, but these effects may diminish after discontinuing the drug.

This study found that SZ95 sebocytes and HaCaT keratinocytes exhibit distinct enzyme expressions and activities, implicating their different roles in androgen metabolism and homeostasis in vitro.

This review discusses the role of cytochrome P450 enzymes in skin metabolism and drug development for skin diseases, highlighting their importance and suggesting further research, but reports no new experimental findings.

This study found that the binding of finasteride to the enzyme 5a-reductase occurs at a slower rate than previously assumed, complicating the estimation of its real inhibitory constant.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This review outlines the functional anatomy, pathology, and molecular mechanisms of androgenetic alopecia, emphasizing the need for multi-omics approaches to better understand this condition's biology.

This review examines the diverse roles of SRD5α enzymes across species, focusing on their involvement in steroid synthesis, sexual development, and various physiological processes, but reports no new clinical results.

This systematic review found that topical adenosine may increase hair thickness and density while reducing hair loss, but the strength of evidence is low due to issues with trial design and sample size.

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

This study highlights the role of abnormal DNA methylation in skin disorders such as atopic dermatitis and psoriasis, suggesting these epigenetic changes may serve as biomarkers and targets for potential treatments.

This study developed solid lipid nanoparticles for delivering a shRNA-encoding plasmid that effectively reduced 5α-reductase enzyme levels in vitro without significant cytotoxicity, suggesting potential therapeutic applications.

This review discusses the biologically active compounds in Maxillariinae orchids, highlighting 62 semiochemicals with medical potential, but reports no new clinical findings.

In this case study, researchers observed that steroidogenesis from adrenal androgens in prostate cancer tissues may explain progression in a 74-year-old man with low circulating testosterone.

This study found that Camellia oleifera seed shell polyphenols and 1,3,6-tri-O-galloylglucose improved androgenetic alopecia symptoms in mice by reducing DHT levels and activating specific hair growth pathways.

This review discusses genetic and pharmacogenetic insights, along with RNA interference technologies, for developing personalized therapies for androgenetic alopecia, yet presents no new clinical results.

This study found that early postnatal androgen activity affects the long-term expression of hormone receptors differently in female Wistar rats, influencing neural system programming during development.

In this study, dihydroartemisinin reduced prostate enlargement and related markers in a rat model of benign prostatic hyperplasia, suggesting its potential as a therapeutic agent.

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

A new method was developed to accurately measure enzyme activity related to prostate health.